Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
The route is determined by the clinical goal: injectable for systemic or musculoskeletal use, oral for gut-specific applications
Clinical data shows that adding GIP agonism produces an additional 3-5% weight loss compared to GLP-1/GIP dual therapy alone
Insomnia is addressable with morning dosing
What is the name of the study that was conducted to grant approval for such ground-breaking therapy
A lower 4mg weekly dose also resulted in impressive weight loss results, with an average loss of 17% over 48 weeks and: 92% of participants lost at least 5% of their starting body weight 75% lost at least 10% of their body weight 60% lost at least 15% of their starting weight Retatrutide vs Mounjaro In clinical trials, the active ingredient in Mounjaro, tirzepatide, results in an average weight loss of 22.5% at the highest 15mg per week dose over 72 weeks
